10-Q: McKesson Reports Mixed Q2 Results Amidst Restructuring and Divestiture

McKesson's Q2 results show a revenue increase but a significant drop in net income due to restructuring charges and a divestiture.

Summary

• McKesson Corporation's Q2 2025 revenues increased by 21% to $93.651 billion compared to $77.215 billion in Q2 2024, while six-month revenues increased by 14% to $172.934 billion compared to $151.698 billion in the prior year.
• Gross profit for the quarter rose by 6% to $3.248 billion, and for the six months by 5% to $6.400 billion.
• However, net income attributable to McKesson Corporation decreased significantly to $241 million in Q2 2025 from $664 million in Q2 2024, and to $1.156 billion for the six months ended September 30, 2024 from $1.622 billion in the prior year.
• Diluted earnings per share also fell to $1.87 from $4.92 in Q2 2024, and to $8.89 from $11.95 for the six months ended September 30, 2024.
• The company recorded a $643 million charge related to the divestiture of its Canadian retail business, impacting operating expenses.
• Restructuring charges totaled $227 million for the quarter and $244 million for the six months, related to enterprise-wide initiatives.
• The company also recognized a net discrete tax benefit of $150 million for the six months ended September 30, 2024, including $58 million related to a change in tax status of a foreign affiliate.
• McKesson repurchased 2.9 million shares of common stock for $1.5 billion in Q2 2025 and $2.0 billion for the six months ended September 30, 2024, and increased its share repurchase authorization by $4.0 billion.
• The company also completed a public offering of 4.25% Notes due September 15, 2029, for $500 million and redeemed its 5.25% Notes due February 15, 2026.

Sentiment

Score: 4

Explanation: The document presents mixed results with strong revenue growth offset by significant declines in net income and earnings per share. The restructuring and divestiture charges, along with ongoing litigation risks, contribute to a negative sentiment. However, the share repurchase program and debt offering are positive signals.

Positives

• Revenues increased by 21% in Q2 2025 and 14% for the six months ended September 30, 2024, driven by market growth in the U.S. Pharmaceutical segment and higher volumes in the International segment.
• Gross profit increased by 6% in Q2 2025 and 5% for the six months ended September 30, 2024, primarily in the U.S. Pharmaceutical segment.
• The company recognized a net discrete tax benefit of $150 million for the six months ended September 30, 2024.
• The company increased its share repurchase authorization by $4.0 billion.
• The company completed a public offering of 4.25% Notes due September 15, 2029, for $500 million.

Negatives

• Net income attributable to McKesson Corporation decreased significantly to $241 million in Q2 2025 and $1.156 billion for the six months ended September 30, 2024.
• Diluted earnings per share fell to $1.87 in Q2 2025 and $8.89 for the six months ended September 30, 2024.
• A $643 million charge was recorded due to the divestiture of the Canadian retail business.
• Restructuring charges totaled $227 million for the quarter and $244 million for the six months.

Risks

• The company faces ongoing risks related to opioid-related litigation, with a total estimated liability of $6.4 billion.
• The company is subject to various claims and legal proceedings, including those related to the distribution of controlled substances.
• The company is exposed to fluctuations in interest rates and foreign currency exchange rates.
• The company is subject to audit by taxing authorities in various U.S. states and foreign jurisdictions for fiscal years 2016 through the current fiscal year.
• The company is subject to risks related to government actions, increased regulatory uncertainty, and material changes in key market assumptions.

Future Outlook

The company anticipates that it will continue to pay quarterly cash dividends in the future, but the payment and amount of future dividends remain within the discretion of the Board. The company expects the restructuring programs to be substantially complete in fiscal 2028.

Industry Context

The results reflect the ongoing challenges and changes in the healthcare industry, including drug pricing pressures, supply chain dynamics, and the impact of litigation. The divestiture of the Canadian retail business and the restructuring initiatives indicate a strategic shift towards focusing on core growth areas.

Comparison to Industry Standards

• McKesson's revenue growth of 21% in Q2 2025 is strong compared to some of its peers in the pharmaceutical distribution industry, but the significant drop in net income is a concern.
• The restructuring charges and divestiture costs are substantial and may be higher than those of some competitors, indicating a more aggressive approach to streamlining operations.
• The company's share repurchase program is a positive sign for investors, but the impact on earnings per share needs to be monitored.
• The company's debt levels and interest expenses are also important factors to consider in comparison to industry benchmarks.
• The ongoing opioid litigation and related liabilities are a significant risk factor that is unique to McKesson and a few other major distributors.

Legal Proceedings

• The company is involved in numerous legal proceedings related to the distribution of controlled substances.
• The company has reached proposed settlements with representatives of nationwide groups of acute care hospitals and certain third-party payors.
• The company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs.
• The company is also a defendant in four opioid-related cases pending in Canada.
• The company is also involved in other litigation and claims, including a case related to unsolicited marketing faxes and a qui tam complaint alleging violations of the Anti-Kickback Statute and federal False Claims Act.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and earnings per share, but also benefit from the share repurchase program.
• Employees are affected by the restructuring initiatives, which include headcount reductions.
• Customers may experience changes in service due to the divestiture of the Canadian retail business.
• Suppliers may be impacted by the company's restructuring and cost optimization efforts.
• Creditors are affected by the company's debt levels and interest expenses.

Next Steps

• The company will continue to execute its restructuring initiatives.
• The company will work to complete the sale of its Canadian retail business.
• The company will continue to manage its opioid-related litigation and liabilities.
• The company will continue to monitor and manage its debt levels and interest expenses.
• The company will continue to evaluate its strategic growth initiatives.

Key Dates

Keywords

McKesson, pharmaceutical distribution, healthcare services, restructuring, divestiture, opioid litigation, financial results, share repurchase, debt offering, earnings per share